Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2023-11-13 10:00:00
Looking ahead with new partners
- Revenue in the period amounted to kSEK 45 (1,967). Revenue includes sales of Egoo.
Health devices and capsules for the device. Revenue in Q3 is solely from test orders of
CRP capsules and Egoo systems.
- EBITDA for the period amounted to kSEK -6,660 (-14,850), and net loss kSEK -8,926
- The total cash flow in the third quarter amounted to kSEK -3,631 (-21,766).
- Earnings per share before/after dilution for the quarter amounted to SEK -0,01 (-1.34),
- Revenue in the period amounted to kSEK 214 (16,897). Revenue includes sales of
- EBITDA for the period amounted to kSEK -34,521 (-51,768), and net loss kSEK -48,410
- The total cash flow from January to September amounted to kSEK -7,848 (-61,479).
- Earnings per share before/after dilution for the first 3 quarters of 2023 amounted to
SEK -0.14 (-3.62), calculated on weighted average number of shares in the period.
- Directed issue of convertibles
On August 3rd the board of directors of Qlife Holding AB ("Qlife" or the "Company") has,
pursuant to the authorization granted by the annual general meeting on 4 May 2023, resolved
on a directed issue of a convertible loan raising gross proceeds of SEK 4,647,035 prior to
deduction of transaction costs. The convertible loan is expected to satisfy the Company's
financing need until the end of 2023.
- Qlife signs letter of intent with major Chinese industry partner Hipro.
Biotechnology, to introduce Egoo Health to the Chinese market. Qlife anticipate finalizing a
comprehensive collaboration agreement by the end of 2023.
The collaboration will be executed in two distinct phases:
1. Regulatory Approvals: Hipro Biotechnology will navigate the regulatory landscape to secure
vital approvals from the China Food and Drug Administration (CFDA) for Egoo Health which
consist of the software, hardware and three test capsules. Hipro Biotechnology will cover all
associated costs during the approval phase for Egoo Health.
2. Commercialization in China: Following regulatory approvals, Hipro Biotechnology will
lead the commercialization of Egoo Health in China, which includes marketing, sales, and
distribution through Hipro's distribution network directly to Chinese hospitals, along with
overseeing the associated financial responsibilities.
Significant events after the end of third quarter of 2023
- Qlife Holding announces the outcome of the exercise of warrants series TO 3
series TO 3, which were issued in connection with the Company's rights issue of units in April
2023 (the "Rights Issue"). The subscription rate was approximately 0.02 per cent and Qlife
thereby received approximately SEK 14 thousand before issue costs.
In total, Qlife issued 622,348,940 units in the Rights Issue, each consisting of one (1) share
and one (1) warrant series TO 3. One (1) warrant entitled the right to subscribe for one (1)
new share in the Company at a fixed exercise price of SEK 0.11 per share, which exceeded
the Company's share price during the exercise period of the warrants that ran from 11 - 29
September 2023.
The outcome showed that 126,250 warrants were utilized for subscription of 126,250 shares,
meaning a subscription rate of approximately 0.02 per cent. Exercised warrants have been
replaced with interim shares pending registration with the Swedish Companies Registration
Office. The interim shares has been converted into shares during week 40, 2023.
Through the exercise of the warrants the Company received approximately SEK 14
thousand before issue costs. The total number of shares in Qlife increases by 126,250, from
645,435,499 to 645,561,749. The share capital in Qlife increases by SEK 10,100.00, from SEK
51,634,839.92 to SEK 51,644,939.92.
Link to Q3 report on Qlife Holdings webpage (https://qlifeholding.com/sites/default/files/2023-11/Qlife_Q3_2023.pdf)